Treatment Sequencing in HER2+ mBC: Real-World Data & Key Considerations in Third-Line Treatment Selection
Experts discuss treatment options for HER2-positive metastatic breast cancer following progression on trastuzumab deruxtecan (T-DXd), weighing real-world data on tucatinib-capecitabine-trastuzumab versus T-DM1, considering factors such as resistance mechanisms, administration preferences, and side effect management.
EP: 1.Treatment Selection and Sequencing in Third Line Settings and Beyond
EP: 2.Understanding Janet's Journey: Navigating HER2+ Metastatic Breast Cancer & Treatment Options
EP: 3.Exploring Third-Line Options in HER2+ mBC: Janet’s Case & Key Trial Insights from HER2CLIMB and EMILIA
Now Viewing
EP: 4.Treatment Sequencing in HER2+ mBC: Real-World Data & Key Considerations in Third-Line Treatment Selection
EP: 5.Managing Oral Treatments and Patient Support Strategies in HER2+ mBC: Multidisciplinary Perspectives
Video content above is prompted by the following:
- What are the available treatment options after progression on trastuzumab deruxtecan (Tdxd), and how do real-world data support the use of tucatinib-based regimens or T-DM1?
- How does the choice between tucatinib-capecitabine-trastuzumab (HER2CLIMB regimen) and T-DM1 depend on patient-specific factors such as toxicity, prior treatment exposure, and logistical considerations?
- How do different mechanisms of HER2 inhibition influence treatment sequencing, and does prior exposure to tyrosine kinase inhibitors (TKIs) impact the efficacy of T-DM1?
Recent Videos
Related Content
